Ilirjana Bajrami and colleagues’ study unveiled a remarkable discovery, revealing synthetic lethality between the inhibition of ROS proto-oncogene 1 (ROS1) and the E-cadherin-deficient breast cancer subtype. The gene discussed is ROS1; the disease is breast carcinoma.